Life science start-ups attract experienced board members

Microcaps apoints Dragan Grabulovski and Ronald Kogens as members of the board of directors. Gael Hedou joins Avrion Therapeutics as investor and chairman of the board. Lunaphore announces the formation of a scientific advisory board.

Microcaps, a Zurich based company developing a new gold standard in microencapsulation, announced the appointment of Dragan Grabulovski and Ronald Kogens as independent members of the Board of Directors. Dragan Grabulovski is the former co-founder and CSO of Covagen (acquired in 2014 by Johnson & Johnson). Since 2015, he has worked as a biotech consultant and serial entrepreneur. Ronald Kogens is a partner and tech lawyer at Froriep, a Swiss based law firm. He specializes in VC-financing and financial market law with a focus on early-stage, disruptive technologies and life science. Founded in early 2019, the ETH Zürich based tech startup Microcaps will bring Swiss precision to the world of microencapsulation. The technology has its largest impact potential in the fields of pharmaceuticals, nutrition and cosmetics. 

Avrion Therapeutics elects Gael Hedou as new Chairman

Avrion Therapeutics was founded in 2020 based on more than 10 years of research from the Brain Mind Institute and Gene Therapy Platform at the Swiss Federal Institute of Technology Lausanne (EPFL). Avrion has developed an innovative gene therapy platform. Gene therapies can provide benefit through modulation of gene function and typically require a single administration of the treatment. Avrion's first clinical candidate gene therapy product, AVR-001, is preparing to enter IND-enabling studies to treat patients with a form of motor neuron disease (amyotrophic lateral sclerosis - ALS). The Basel-based company announced the election of Gael Hedou as the new Chairman of the Board of Directors. He is the founder and former CEO of Relief Therapeutics Holding AG. Hedou also invested in Avrion Therapeutics. 

Lunaphore announces new Scientific Advisory Board

Lunaphore Technologies, a Swiss life-sciences company developing innovative next-generation equipment for cancer research, announces the formation of its Scientific Advisory Board (SAB) with the appointment of two experts in the immuno-oncology (I-O) field to provide strategic advisory support to the company’s R&D activities and product portfolio development. Paolo A. Ascierto is the Director of the Department of Melanoma, Cancer Immunotherapy and Development Therapeutics at the National Tumor Institute in Naples, Italy. Jérôme Galon is the Director of Research at INSERM (French National Institute of Health and Medical Research), and Head of the Laboratory of Integrative Cancer Immunology at the Cordeliers Research Center in Paris, France.